TPIDB > 臨床試驗主持人
臨床試驗主持人
更新時間：2023-09-19
陳鈴津Yu, Alice
- 協同主持人
- 執行臨床試驗年資 23 年 9 個月
-
aliceyu@cgmh.org.tw
-
g27yummy@gmail.com
發表文獻
8筆
1
Yu A.L.*, Gilman A.L., Ozkaynak M.F., London W.B., Kreissman S.G., Chen H.X., Smith M., Anderson B., Villablanca J.G., Matthay K.K., Shimada H., Grupp S.A., Seeger R., Reynolds C.P., Buxton A., Reisfeld R.A., Gillies S.D., Cohn S.L., Maris J.M., Sondel P.M. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 2010, 363(14): 1324-1334
2
Mody R., Naranjo A., Van Ryn C., Yu A.L., London W.B., Shulkin B.L., Parisi M.T., Servaes S., Diccianni M.B., Sondel P.M., Maris J.M., Park J.R., Bagatell R.* Irinotecan-temozolomide with temsirolimus or Dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomized, phase 2 trial. Lancet Oncology 2017, 18(7): 946-57.
3
Ladenstein, R., Potschger, U., Valteau-Couanet, D., Luksch, R., Castel, V., Yaniv, I., Laureys, G., Brock, P., Michon, J.M., Owens, C., Trahair, T., Chan, G.C.F., Ruud, E., Schroeder, H., Beck Popovic, M., Schreier, G., Loibner, H., Ambros, P., Holmes, K., Castellani, M.R., Gaze, M.N., Garaventa, A., Pearson, A.D.J. & Lode, H.N. (2018) Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial. Lancet Oncol 19:1617-1629. https://doi.org/10.1016/S1470-2045(18)30578-3
4
Ozkaynak M.*, London W., Naranjo A., Diccianni M., Tenney S., Smith M., Messer K., Gilman A., Seeger R., Reynolds C.P., Smith M., Shulkin B., Parisi M., Maris J., Park J., Sondel P., and Yu A.L.*. A Comprehensive Safety Trial of Ch14.18 with GM-CSF, IL-2 and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: COG ANBL0931. Frontiers in Immunology 2018, 9:1355.
5
Erbe A.K., Wang W., Carmichael L., Kim K., Mendonca E.A., Song Y., Hess D., Reville P.K., London W.B., Naranjo A., Hank J.A., Diccianni M.B., Reisfeld R.A., Gillies S.D., Matthay K.K., Cohn S.L., Hogarty M.D., Maris J.M., Park J.R., Ozkaynak F., Gilman A., Yu A.L., Sondel P.M.* Neuroblastoma patients’ KIR and KIR-ligand genotypes influence clinical outcome for dinutuximab-based immunotherapy: a report from the Children’s Oncology Group. Clinical Cancer Research 2018, 24(1): 189-96.
6
Mody R., Yu A.L., Naranjo A., Zhang F.F., London W.B., Shulkin B.L., Parisi M.T., Servaes S., Diccianni M.B., Hank J.A., Felder M., Birstler J., Sondel P.M., Asgharzadeh S., Glade-Bender J., Katzenstein H., Maris J.M., Park J.R., Bagatell R. Irinotecan, Temozolomide, and Dinutuximab with GM-CSF in children with refractory or relapsed neuroblastoma: a report from the Children’s Oncology Group. Journal of Clinical Oncology 2020, 38:2160-9.
7
Yu A.L.*, Gilman A.L., Ozkaynak M.F., Naranjo A., Diccianni M.B., Gan J., Hank J.A., Batova A., London W.B., Tenney S.C., Smith M., Shulkin B.L., Parisi M., Matthay K.K., Cohn S.L., Maris J.M., Bagatell R., Park J.R., Sondel P.M., Long-tern follow-up of a Phase III study of ch14.18 (Dinutuximab) + cytokine immunotherapy in children with high-risk neuroblastoma: Children’s Oncology Group study ANBL0032. Clinical Cancer Research 2021, 27(8): 2179-89.
8
Desai, A. V., Gilman, A. L., Ozkaynak, M. F., Naranjo, A., London, W. B., Tenney, S. C., . . . Yu, A. L. (2022). Outcomes Following GD2-Directed Postconsolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children's Oncology Group. J Clin Oncol, JCO2102478. doi:10.1200/JCO.21.02478
